Related Experiment Video
Updated: Feb 3, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
CPX-351: From preclinical studies to future directions
A Sperotto1, G Ciotti2, M Basso3
1UOSD Terapie Cellulari - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy; UOC Oncoematolgia - Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV) - IRCCS - Padova, Italy.
CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, is approved for secondary acute myeloid leukemia (AML). This review covers its development, toxicity, and therapeutic applications.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The standard induction treatment for acute myeloid leukemia (AML) has been the 7+3 regimen.
- Secondary AML presents unique treatment challenges.
- CPX-351 (Vyxeos) offers a novel liposomal formulation of cytarabine and daunorubicin.
Purpose of the Study:
- To review the development of CPX-351 from preclinical research to FDA approval.
- To analyze the efficacy and safety profile of CPX-351.
- To discuss current and potential future applications of CPX-351 in AML treatment.
Main Methods:
- Review of preclinical studies.
- Analysis of clinical trial data.
- Examination of regulatory submission and approval process.
Main Results:
- CPX-351, utilizing CombiPlex technology, demonstrated a synergistic 5:1 ratio of cytarabine and daunorubicin.
- FDA approval in August 2017 for adults with newly diagnosed secondary AML.
- Recent research indicates potential intestinal and heart toxicity.
Conclusions:
- CPX-351 represents a significant advancement in AML therapy.
- Understanding its toxicity profile is crucial for patient management.
- Further research may expand its therapeutic utility in AML and other malignancies.
More Related Videos
06:16An Experimental Approach to Investigating Effects of Artificial Light at Night on Free-Ranging Animals: Implementation, Results, and Directions for Future Research
Published on: February 2, 2022
10:193D Kinematic Gait Analysis for Preclinical Studies in Rodents
Published on: August 3, 2019
Related Concept Videos
Preclinical Development: Overview
Directing Effect of Substituents: meta-Directing Groups
Directing Effect of Substituents: ortho–para-Directing Groups
Directional Terms
Directional Relays
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...